Mime-Version: |
1.0 |
Sender: |
|
Subject: |
|
From: |
|
Date: |
Thu, 22 Jul 1999 15:34:47 -0400 |
Content-Transfer-Encoding: |
7bit |
Content-Type: |
text/plain |
Reply-To: |
|
Parts/Attachments: |
|
|
To : Franoise Railhet
Re : Trimetazidine
Trimetazidine is an antianginal and antiischemic agent which differs
chemically and pharmacologically from beta-blocking agents, nitrates, and
calcium antagonists. Animal studies suggest that this drug is
cardioprotective during ischemic states. It is most commonly used in stable
angina patients, and during angioplasty and coronary artery bypass surgery,
in the absence of significant alterations in coronary blood flow.
There are no data on its transfer to human milk nor many of its kinetic
properties. Peak serum levels after oral doses occur in 2 to 3 hours;
significant and sustained improvement in angina has been observed after 2 to
6 weeks of therapy. Half-line is unknown, but probably about 8 hours.
Although there are few untoward effects, I simply don't know enough about
this product to make recommendations concerning breastfeeding.
Sorry.
Regards
Tom Hale, Ph.D.
***********************************************
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html
|
|
|